Viracta Financial Statements From 2010 to 2024

Stocks . USA . 
Stock . Viracta Therapeutics
VIRX Stock  USD 0.15  0.01  7.14%   
Viracta Therapeutics financial statements provide useful quarterly and yearly information to potential Viracta Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Viracta Therapeutics financial statements helps investors assess Viracta Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Viracta Therapeutics' valuation are summarized below:
Market Capitalization
5.9 M
Earnings Share
(1.10)
We have found one hundred twenty available fundamental trend indicators for Viracta Therapeutics, which can be analyzed and compared to other ratios and to its competition. All investors should make sure to double-check all of Viracta Therapeutics current market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 20.9 M in 2024. Enterprise Value is likely to drop to about 33.5 M in 2024

Viracta Therapeutics Total Revenue

0.0

Check Viracta Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viracta Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 324.1 K, Interest Expense of 3.9 M or Selling General Administrative of 13.7 M, as well as many indicators such as Price To Sales Ratio of 5.9, Dividend Yield of 0.0 or PTB Ratio of 1.14. Viracta financial statements analysis is a perfect complement when working with Viracta Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Viracta Therapeutics Correlation against competitors.
For more information on how to buy Viracta Stock please use our How to Invest in Viracta Therapeutics guide.

Viracta Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets54.4 M56.7 M53.3 M
Pretty Stable
Short and Long Term Debt Total14.3 M25.6 M14.5 M
Pretty Stable
Other Current Liabilities5.5 M10.1 M7.2 M
Slightly volatile
Total Current Liabilities40.3 M38.4 M18.6 M
Pretty Stable
Property Plant And Equipment Net749.7 K464 K573.1 K
Pretty Stable
Current Deferred Revenue0.860.92.3 M
Slightly volatile
Accounts Payable1.7 M2.4 M1.8 M
Slightly volatile
Cash24.1 M12.3 M26.5 M
Slightly volatile
Non Current Assets Total1.1 M1.7 M1.1 M
Pretty Stable
Non Currrent Assets Other1.3 M1.3 M874.1 K
Slightly volatile
Cash And Short Term Investments51.5 M53.7 M50.8 M
Pretty Stable
Common Stock Total Equity5 K4.6 K4.8 K
Very volatile
Common Stock Shares Outstanding40.6 M38.6 M10.9 M
Slightly volatile
Liabilities And Stockholders Equity54.4 M56.7 M53.3 M
Pretty Stable
Other Current Assets1.6 M1.1 M1.6 M
Pretty Stable
Total Liabilities27.6 M38.4 M30.5 M
Very volatile
Property Plant And Equipment Gross717.8 K464 K520.5 K
Pretty Stable
Total Current Assets52.9 M55 M52.2 M
Pretty Stable
Short Term Debt27.1 M25.8 M8 M
Slightly volatile
Common Stock4.9 K4.6 K4.8 K
Very volatile
Long Term Debt30 M28.6 M12.2 M
Slightly volatile
Capital Surpluse436.4 M243.6 M539.7 M
Slightly volatile
Property Plant Equipment245.8 K170.2 K133.2 K
Slightly volatile
Other Liabilities322.2 K362.4 K394.6 K
Slightly volatile
Capital Lease Obligations442.2 K282 K838.2 K
Slightly volatile
Short and Long Term Debt30.5 M29.1 M8.1 M
Slightly volatile
Preferred Stock Total Equity4.4 M4.9 M5.4 M
Slightly volatile
Capital Stock4.5 M6.3 M1.4 M
Slightly volatile
Net Working Capital15.8 M16.6 M44.2 M
Very volatile
Long Term Debt Total16.3 M28.6 M8.5 M
Slightly volatile
Net Receivables476.4 K281 K839.2 K
Slightly volatile

Viracta Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization324.1 K492 K207.7 K
Pretty Stable
Interest Expense3.9 M3.7 M1.5 M
Pretty Stable
Selling General Administrative13.7 M17.3 M13.2 M
Pretty Stable
Other Operating Expenses29.3 M50.7 M36.5 M
Pretty Stable
Research Development19.6 M33.4 M23.9 M
Slightly volatile
Total Operating Expenses29.3 M50.7 M36.5 M
Pretty Stable
Income Tax Expense696.7 K663.5 K6.9 M
Pretty Stable
Interest Income3.4 M3.2 M1.5 M
Very volatile
Selling And Marketing Expenses420.7 K442.8 K6.8 M
Slightly volatile
Cost Of Revenue250.8 K492 K98.9 K
Slightly volatile
Reconciled Depreciation232.7 K426 K93.2 K
Slightly volatile
Non Recurring70.8 M79.6 M86.7 M
Slightly volatile

Viracta Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation7.3 M7.6 M88.9 M
Slightly volatile
Begin Period Cash Flow23.8 M36.8 M25.9 M
Slightly volatile
Other Cashflows From Financing Activities132.1 K139 K373.6 M
Slightly volatile
Depreciation324.1 K492 K207.7 K
Pretty Stable
Total Cash From Financing Activities416.1 K438 K27.9 M
Pretty Stable
End Period Cash Flow24.1 M12.3 M26.5 M
Slightly volatile
Sale Purchase Of Stock2.2 M2.3 M23.4 M
Slightly volatile
Change To Operating Activities827.5 K1.1 M563.3 K
Slightly volatile
Change To Netincome23.1 M15.6 M9.8 M
Slightly volatile
Change To Liabilities1.2 M1.2 M820.7 K
Slightly volatile
Issuance Of Capital Stock1.4 M1.4 M33.6 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio5.96.2149.3133
Slightly volatile
Average Payables2 M1.3 M1.3 M
Very volatile
Stock Based Compensation To Revenue3.173.337.1182
Slightly volatile
Capex To Depreciation0.270.28052.9813
Pretty Stable
Sales General And Administrative To Revenue53.8151.2519.4698
Slightly volatile
Research And Ddevelopement To Revenue10610145.6481
Slightly volatile
Capex To Revenue0.230.410.212
Slightly volatile
Cash Per Share1.321.3901121
Slightly volatile
Income Quality0.90.78130.8366
Pretty Stable
Current Ratio1.361.43244.0614
Pretty Stable
Graham Number3.573.7559365
Slightly volatile
Capex Per Share0.00340.00361.9251
Slightly volatile
Revenue Per Share1.411.4920.5492
Slightly volatile
Interest Debt Per Share0.720.757618.2094
Slightly volatile
Debt To Assets0.470.45080.2621
Pretty Stable
Quick Ratio1.361.43594.0677
Pretty Stable
Net Income Per E B T0.870.911.055
Very volatile
Cash Ratio0.30.3212.3444
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.141.00351.0312
Slightly volatile
Fixed Asset Turnover0.09960.1118
Pretty Stable
Debt Ratio0.470.45080.2621
Pretty Stable
Price Sales Ratio5.96.2149.3133
Slightly volatile
Asset Turnover0.00270.00290.0677
Slightly volatile
Gross Profit Margin0.80.841.1517
Very volatile

Viracta Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap20.9 M22 M212.1 M
Slightly volatile

Viracta Fundamental Market Drivers

Cash And Short Term Investments53.7 M

Viracta Upcoming Events

11th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
11th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Viracta Therapeutics Financial Statements

Viracta Therapeutics investors use historical fundamental indicators, such as Viracta Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Viracta Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue 0.90  0.86 
Cost Of Revenue492 K250.8 K
Stock Based Compensation To Revenue 3.33  3.17 
Sales General And Administrative To Revenue 51.25  53.81 
Research And Ddevelopement To Revenue 101.00  106.05 
Capex To Revenue 0.41  0.23 
Revenue Per Share 1.49  1.41 
Ebit Per Revenue(180.31)(171.29)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
ESRTEmpire State Realty
CCitigroup
CCitigroup

Additional Tools for Viracta Stock Analysis

When running Viracta Therapeutics' price analysis, check to measure Viracta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viracta Therapeutics is operating at the current time. Most of Viracta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viracta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viracta Therapeutics' price. Additionally, you may evaluate how the addition of Viracta Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY